← Back to Search

Behavioral Intervention

Intervention for Overmedication

N/A

Recruiting

Led By Ariel Green, MD, MPH, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

Study Summary

This trial aims to test a pharmacist-led program to help people with dementia and their care partners reduce the number of medications they are taking. The program includes an educational brochure, a telehealth visit with a

Who is the study for?

This trial is for people aged 65 or older with dementia, taking five or more medications, and have visited their primary care clinic in the past year. A family member or companion over 21 who helps manage their meds must also participate. It's not for those in long-term care or hospice, nor for those unable to communicate by phone in English.Check my eligibility

What is being tested?

The study tests a pharmacist-led intervention to reduce unnecessary medications among patients with dementia. It includes an educational brochure, a telehealth visit discussing medication benefits and harms, and tailored recommendations from the pharmacist to the patient's doctor.See study design

What are the potential side effects?

Since this trial involves deprescribing (reducing or stopping medications), potential side effects may include withdrawal symptoms from stopping certain drugs or changes in how other conditions are managed due to altered medication regimens.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of patients who stop one or more medications

Secondary outcome measures

Proportion of patients who start one or more new medications

Proportion of patients who stop one or more potentially inappropriate medication (PIM)

Total number of medications

Other outcome measures

Shared decision-making as assessed by CollaboRATE

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: InterventionExperimental Treatment1 Intervention

The intervention consists of the following: Mailing a deprescribing educational brochure to PLWD and care partners; PLWD and/or care partners will receive a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; Pharmacist-primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP.

Group II: Delayed intervention (wait list control)Active Control1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pharmacist-led deprescribing intervention

2021

N/A

~140

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,275 Previous Clinical Trials

14,840,358 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,694 Previous Clinical Trials

28,027,045 Total Patients Enrolled

Ariel Green, MD, MPH, PhDPrincipal InvestigatorJohns Hopkins University

2 Previous Clinical Trials

159 Total Patients Enrolled

~187 spots leftby May 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.